title: Buruli ulcer disease in Republic of the Congo.
authors.forename: Estelle
authors.initials: E
authors.lastname: Marion
authors.forename: Damas
authors.initials: D
authors.lastname: Obvala
authors.forename: Jeremie
authors.initials: J
authors.lastname: Babonneau
authors.forename: Marie
authors.initials: M
authors.lastname: Kempf
authors.forename: Kingsley B
authors.initials: KB
authors.lastname: Asiedu
authors.forename: Laurent
authors.initials: L
authors.lastname: Marsollier
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D054312:Buruli Ulcer / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003223:Congo / Q000453:epidemiology; D062665:Epidemiological Monitoring; D005260:Female; D006801:Humans; D008297:Male; D019911:Mycobacterium ulcerans / Q000187:drug effects / Q000302:isolation & purification*; D058069:Neglected Diseases; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D012293:Rifampin; D013307:Streptomycin
keywords: Buruli ulcer; Congo Brazzaville; Mycobacterium ulcerans; Republic of the Congo; bacteria; necrotic disease; skin disease; tropical disease